Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Adjuvant cardioprotection in cardiac surgery: update

R. Wagner, P. Piler, Z. Gabbasov, J. Maruyama, K. Maruyama, J. Nicovsky, P. Kruzliak,

. 2014 ; 2014 (-) : 808096. [pub] 20140819

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000625

Cardiac surgery patients are now more risky in terms of age, comorbidities, and the need for complex procedures. It brings about reperfusion injury, which leads to dysfunction and/or loss of part of the myocardium. These groups of patients have a higher incidence of postoperative complications and mortality. One way of augmenting intraoperative myocardial protection is the phenomenon of myocardial conditioning, elicited with brief nonlethal episodes of ischaemia-reperfusion. In addition, drugs are being tested that mimic ischaemic conditioning. Such cardioprotective techniques are mainly focused on reperfusion injury, a complex response of the organism to the restoration of coronary blood flow in ischaemic tissue, which can lead to cell death. Extensive research over the last three decades has revealed the basic mechanisms of reperfusion injury and myocardial conditioning, suggesting its therapeutic potential. But despite the enormous efforts that have been expended in preclinical studies, almost all cardioprotective therapies have failed in the third phase of clinical trials. One reason is that evolutionary young cellular mechanisms of protection against oxygen handling are not very robust. Ischaemic conditioning, which is among these, is also limited by this. At present, the prevailing belief is that such options of treatment exist, but their full employment will not occur until subquestions and methodological issues with the transfer into clinical practice have been resolved.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000625
003      
CZ-PrNML
005      
20160122104920.0
007      
ta
008      
160108s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2014/808096 $2 doi
035    __
$a (PubMed)25215293
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wagner, Robert $u Department of Cardiovascular Anesthesiology, Centre of Cardiovascular and Transplant Surgery, Pekarska 53, 656 91 Brno, Czech Republic ; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic.
245    10
$a Adjuvant cardioprotection in cardiac surgery: update / $c R. Wagner, P. Piler, Z. Gabbasov, J. Maruyama, K. Maruyama, J. Nicovsky, P. Kruzliak,
520    9_
$a Cardiac surgery patients are now more risky in terms of age, comorbidities, and the need for complex procedures. It brings about reperfusion injury, which leads to dysfunction and/or loss of part of the myocardium. These groups of patients have a higher incidence of postoperative complications and mortality. One way of augmenting intraoperative myocardial protection is the phenomenon of myocardial conditioning, elicited with brief nonlethal episodes of ischaemia-reperfusion. In addition, drugs are being tested that mimic ischaemic conditioning. Such cardioprotective techniques are mainly focused on reperfusion injury, a complex response of the organism to the restoration of coronary blood flow in ischaemic tissue, which can lead to cell death. Extensive research over the last three decades has revealed the basic mechanisms of reperfusion injury and myocardial conditioning, suggesting its therapeutic potential. But despite the enormous efforts that have been expended in preclinical studies, almost all cardioprotective therapies have failed in the third phase of clinical trials. One reason is that evolutionary young cellular mechanisms of protection against oxygen handling are not very robust. Ischaemic conditioning, which is among these, is also limited by this. At present, the prevailing belief is that such options of treatment exist, but their full employment will not occur until subquestions and methodological issues with the transfer into clinical practice have been resolved.
650    _2
$a adjuvancia farmaceutická $x terapeutické užití $7 D000277
650    12
$a kardiochirurgické výkony $x škodlivé účinky $7 D006348
650    _2
$a kardiotonika $x terapeutické užití $7 D002316
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a lidé $7 D006801
650    _2
$a ischemický postconditioning $7 D057775
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Piler, Pavel $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic ; Department of Cardiovascular Surgery, Centre of Cardiovascular and Transplant Surgery, Pekarska 53, 656 91 Brno, Czech Republic.
700    1_
$a Gabbasov, Zufar $u Institute of Experimental Cardiology, Russian Cardiology and Research Complex, 3rd Cherepkovskaya 15-A, 12552 Moscow, Russia.
700    1_
$a Maruyama, Junko $u Department of Anesthesiology and Critical Care Medicine, Mie University School of Medicine, 1577 Kurimamachiya-cho, Tsu City, Mie Prefecture 514-8507, Japan ; Department of Clinical Engineering, Suzuka University of Medical Science, 1001-1 Kishiokacho, Suzuka, Mie Prefecture 510-0226, Japan.
700    1_
$a Maruyama, Kazuo $u Department of Anesthesiology and Critical Care Medicine, Mie University School of Medicine, 1577 Kurimamachiya-cho, Tsu City, Mie Prefecture 514-8507, Japan ; Department of Clinical Engineering, Suzuka University of Medical Science, 1001-1 Kishiokacho, Suzuka, Mie Prefecture 510-0226, Japan.
700    1_
$a Nicovsky, Jiri $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic ; Department of Cardiovascular Surgery, Centre of Cardiovascular and Transplant Surgery, Pekarska 53, 656 91 Brno, Czech Republic.
700    1_
$a Kruzliak, Peter $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic.
773    0_
$w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2014, č. - (2014), s. 808096
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25215293 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160122105040 $b ABA008
999    __
$a ok $b bmc $g 1102906 $s 924831
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 2014 $c - $d 808096 $e 20140819 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...